Ketamine and rapidly acting antidepressants: Breaking the speed of sound or light?

Australian and New Zealand Journal of Psychiatry

Volumn 52, Issue 11, 2018, Pages 1026-1029

  Berk, Michael ^a,b,c,d   Loo, Collen ^e   Davey, Christopher G ^b,c   Harvey, Brian H ^f  

^a DEAKIN UNIVERSITY   (Australia)

^b THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f NORTH WEST UNIVERSITY   (South Africa)

Author keywords

antidepressant; depression; Ketamine; psychiatry; treatment

Indexed keywords

ANTIDEPRESSANT AGENT; KETAMINE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; DEPRESSION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; TACHYPHYLAXIS; TREATMENT RESPONSE; TIME FACTOR;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; KETAMINE; TIME FACTORS;

EID: 85049857649     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867418783567     Document Type: Article

References (20)

1. aan het Rot M, Collins KA, Murrough JW. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 67: 139–145
2. Bonnet U, (2015) Long-term ketamine self-injections in major depressive disorder: Focus on tolerance in ketamine’s antidepressant response and the development of ketamine addiction. Journal of Psychoactive Drugs 847: 276–285
3. Brand SJ, Moller M, Harvey BH, (2015) A review of biomarkers in mood and psychotic disorders: A dissection of clinical vs. preclinical correlates. Current Neuropharmacology 13: 324–368
4. Gálvez V, O’Keefe E, Cotiga L. (2014) Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: A case report. Biological Psychiatry 76: e1–2
5. Harvey BH, (2008) Is major depressive disorder a metabolic encephalopathy? Human Psychopharmacology 23: 371–384
6. Harvey BH, Slabbert FN, (2014) New insights on the antidepressant discontinuation syndrome. Human Psychopharmacology 29: 503–516
7. Harvey BH, Hamer M, Louw R. (2013) Metabolic and glutathione redox markers associated with brain-derived neurotrophic factor in depressed African men and women. Evidence for counter-regulation? Neuropsychobiology 67: 33–40
8. Harvey BH, McEwen BS, Stein DJ, (2003) Neurobiology of antidepressant withdrawal: Implications for the longitudinal outcome of depression. Biological Psychiatry 54: 1105–1117
9. Harvey BH, Retief R, Nel A. (2006) Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: Role of 5HT 2A/C-receptors. Metabolic Brain Disease 21: 211–220
10. Holtzheimer PE, Husain MM, Lisanby SH. (2017) Subcallosal cingulate deep brain stimulation for treatment-resistant depression: A multisite, randomised, sham-controlled trial. Lancet Psychiatry 4: 839–849
11. Lembke A, Papac J, Humphreys K, (2018) Our other prescription drug problem. New England Journal of Medicine 378: 693–695
12. Mayberg HS, Lozano AM, Voon V. (2005) Deep brain stimulation for treatment-resistant depression. Neuron 45: 651–660
13. Möller M, Swanepoel T, Harvey BH, (2015) Neurodevelopmental animal models reveal the convergent role of neurotransmitter systems, inflammation, and oxidative stress as biomarkers of Schizophrenia: Implications for novel drug development. ACS Chemical Neuroscience 6: 987–1016
14. Mouton M, Harvey BH, Cockeran M. (2016) The long-term effects of methamphetamine exposure during pre-adolescence on depressive-like behaviour in a genetic animal model of depression. Metabolic Brain Disease 31: 63–74
15. Murrough JW, Perez AM, Pillemer S. (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry 74: 250–256
16. Short B, Fong J, Gálvez V. (2018) Side-effects associated with ketamine use in depression: A systematic review. Lancet Psychiatry 5: 65–78
17. Swanepoel T, Möller M, Harvey BH, (2018) N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges. Psychopharmacology 235: 351–368
18. Wohleb ES, Gerhard D, Thomas A. (2017) Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine. Current Neuropharmacology 15: 11–20
19. Workman ER, Niere F, Raab-Graham KF, (2018) Engaging homeostatic plasticity to treat depression. Molecular Psychiatry 23: 26–35
20. Zanos P, Moaddel R, Morris PJ. (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533: 481–486